De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Precigen Beheer

Beheer criteriumcontroles 2/4

De CEO Precigen's is Helen Sabzevari, benoemd in Jan2020, heeft een ambtstermijn van 4.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.72M, bestaande uit 26.9% salaris en 73.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.77% van de aandelen van het bedrijf, ter waarde $ 2.10M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 10.5 jaar.

Belangrijke informatie

Helen Sabzevari

Algemeen directeur

US$3.7m

Totale compensatie

Percentage CEO-salaris	26.9%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	10.5yrs

Recente managementupdates

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Analyse CEO-vergoeding

Hoe is Helen Sabzevari's beloning veranderd ten opzichte van Precigen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$135m
Mar 31 2024	n/a	n/a	-US$97m
Dec 31 2023	US$4m	US$1m	-US$96m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$79m
Dec 31 2022	US$3m	US$1m	-US$80m
Sep 30 2022	n/a	n/a	-US$84m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$108m
Dec 31 2021	US$3m	US$1m	-US$111m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	US$20m	US$1m	-US$104m
Sep 30 2020	n/a	n/a	-US$100m
Jun 30 2020	n/a	n/a	-US$122m
Mar 31 2020	n/a	n/a	-US$138m
Dec 31 2019	US$1m	US$500k	-US$169m
Sep 30 2019	n/a	n/a	-US$373m
Jun 30 2019	n/a	n/a	-US$381m
Mar 31 2019	n/a	n/a	-US$414m
Dec 31 2018	US$3m	US$500k	-US$375m

Compensatie versus markt: De totale vergoeding ($USD 3.72M ) Helen } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Helen is gestegen terwijl het bedrijf verliesgevend is.

CEO

Helen Sabzevari (62 yo)

4.8yrs

Tenure

US$3,719,061

Compensatie

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Randal Kirk	Executive Chairman	16.7yrs	US$600.00k	0.40% $ 979.4k
Helen Sabzevari	President	4.8yrs	US$3.72m	0.77% $ 1.9m
Harry Thomasian	Chief Financial Officer	3yrs	US$1.13m	0.080% $ 196.3k
Rutul Shah	Chief Operating Officer	no data	US$1.04m	0.073% $ 179.5k
Donald Lehr	Chief Legal Officer & Corporate Secretary	13.8yrs	US$1.06m	0.19% $ 460.5k
Jeffrey Perez	Senior Vice President of Intellectual Property Affairs	10.2yrs	US$872.09k	0.26% $ 635.9k
Steven Harasym	VP & Head of Investor Relations	6.8yrs	geen gegevens	geen gegevens
Rob Russell	VP & Head of Human Resources	no data	geen gegevens	geen gegevens
Douglas Brough	Senior VP & Head of Research	no data	geen gegevens	geen gegevens
Bryan Butman	Senior VP & Head of CMC	no data	geen gegevens	geen gegevens
Amy Lankford	Senior VP & Head of Clinical Operations and Regulatory Affairs	1.3yrs	geen gegevens	geen gegevens
Phil Tennant	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Randal Kirk	Executive Chairman	16.7yrs	US$600.00k	0.40% $ 979.4k
Helen Sabzevari	President	4.3yrs	US$3.72m	0.77% $ 1.9m
Jeffrey Kindler	Independent Director	12.9yrs	US$319.00k	0.14% $ 336.6k
Fred Hassan	Independent Director	8.3yrs	US$306.50k	0.36% $ 881.3k
Cesar Alvarez	Independent Director	16.7yrs	US$312.50k	0.20% $ 487.7k
James Turley	Lead Independent Director	10.5yrs	US$312.50k	0.16% $ 404.3k
Steven Frank	Independent Director	16.7yrs	US$300.00k	0.36% $ 876.5k
Nancy Agee	Independent Director	less than a year	geen gegevens	0.0061% $ 15.1k
Vinita Gupta	Independent Director	7.5yrs	US$306.50k	0.16% $ 389.9k

10.5yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PGEN zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.5 jaar).

Precigen Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Precigen, Inc., Annual General Meeting, Jul 05, 2024

President exercised options and sold US$575k worth of stock

Independent Director recently sold US$136k worth of stock

Independent Director recently bought US$688k worth of stock

President exercised options and sold US$58k worth of stock

Recent updates

Consensus revenue estimates fall by 12%

Price target decreased by 41% to US$6.00

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Shareholder dilution

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Precigen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

New minor risk - Share price stability

Precigen, Inc. Announces the Appointment of Phil Tennant as Chief Commercial Officer

Price target increased by 11% to US$10.12

Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response

Price target increased by 11% to US$10.12

Precigen, Inc., Annual General Meeting, Jul 05, 2024

Consensus revenue estimates fall by 10%

Price target increased by 40% to US$9.12

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront